Hancock Mark J, Maher Chris G, Latimer Jane, McLachlan Andrew J, Cooper Chris W, Day Richard O, Spindler Megan F, McAuley James H
Back Pain Research Group, University of Sydney, Sydney, Australia.
Lancet. 2007 Nov 10;370(9599):1638-43. doi: 10.1016/S0140-6736(07)61686-9.
We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or spinal manipulative therapy, or both, would result in faster recovery for patients with acute low back pain receiving recommended first-line care.
240 patients with acute low back pain who had seen their general practitioner and had been given advice and paracetamol were randomly allocated to one of four groups in our community-based study: diclofenac 50 mg twice daily and placebo manipulative therapy (n=60); spinal manipulative therapy and placebo drug (n=60); diclofenac 50 mg twice daily and spinal manipulative therapy (n=60); or double placebo (n=60). The primary outcome was days to recovery from pain assessed by survival curves (log-rank test) in an intention-to-treat analysis. This trial was registered with the Australian Clinical Trials Registry, ACTRN012605000036617.
Neither diclofenac nor spinal manipulative therapy appreciably reduced the number of days until recovery compared with placebo drug or placebo manipulative therapy (diclofenac hazard ratio 1.09, 95% CI 0.84-1.42, p=0.516; spinal manipulative therapy hazard ratio 1.01, 95% CI 0.77-1.31, p=0.955). 237 patients (99%) either recovered or were censored 12 weeks after randomisation. 22 patients had possible adverse reactions including gastrointestinal disturbances, dizziness, and heart palpitations. Half of these patients were in the active diclofenac group, the other half were taking placebo. One patient taking active diclofenac had a suspected hypersensitivity reaction and ceased treatment.
Patients with acute low back pain receiving recommended first-line care do not recover more quickly with the addition of diclofenac or spinal manipulative therapy.
我们旨在研究对于接受推荐的一线治疗的急性腰痛患者,加用非甾体类抗炎药或脊柱推拿疗法,或两者联用,是否会使其恢复得更快。
在我们这项基于社区的研究中,240名看过全科医生并已接受建议及对乙酰氨基酚治疗的急性腰痛患者被随机分配到四组之一:双氯芬酸50毫克每日两次加安慰剂推拿疗法(n = 60);脊柱推拿疗法加安慰剂药物(n = 60);双氯芬酸50毫克每日两次加脊柱推拿疗法(n = 60);或双安慰剂(n = 60)。主要结局是在意向性分析中通过生存曲线(对数秩检验)评估的疼痛恢复天数。该试验已在澳大利亚临床试验注册中心注册,注册号为ACTRN012605000036617。
与安慰剂药物或安慰剂推拿疗法相比,双氯芬酸和脊柱推拿疗法均未明显减少恢复所需天数(双氯芬酸风险比1.09,95%可信区间0.84 - 1.42,p = 0.516;脊柱推拿疗法风险比1.01,95%可信区间0.77 - 1.31,p = 0.955)。237名患者(99%)在随机分组后12周内恢复或被截尾。22名患者出现了可能的不良反应,包括胃肠道不适、头晕和心悸。这些患者中有一半在双氯芬酸治疗组,另一半服用安慰剂。一名服用双氯芬酸的患者出现疑似过敏反应并停止治疗。
接受推荐的一线治疗的急性腰痛患者,加用双氯芬酸或脊柱推拿疗法并不会恢复得更快。